The Path Forward for SGLT Inhibitors in T1D
Heart and kidney complications remain a major concern for people living with type 1 diabetes (T1D). While there are some therapies available to reduce the risk of these complications, the T1D community urgently needs more options. SGLT inhibitors (SGLTi), which have proven effective in people with type 2 diabetes (T2D) and people without diabetes, are […]
What’s Ahead at Our First Clinical & Research Congress
After months and months of preparation, it’s finally here! Breakthrough T1D’s very first Clinical & Research Congress (CRC), a groundbreaking event focused entirely on type 1 diabetes (T1D), is happening this week from October 9-11 in Philadelphia, PA. Bringing Together People United in Our Shared Goal This scientific meeting is a groundbreaking event, uniting T1D […]
Islet Cell Therapies Take the Stage at Public Workshop
Islet cell therapies for type 1 diabetes (T1D) are in the works. In clinical trials, people are coming off external insulin—and experiencing healthy blood sugar levels. Researchers and clinicians are working hard behind the scenes to advance next-generation manufactured islet cell therapies as scalable cures. The momentum is real—and it’s more important than ever to […]
Finerenone Approved for Chronic Kidney Disease Associated With T1D
Finerenone is the First Therapy Approved in 30 Years for Kidney Disease and T1D Today, the U.S. Food and Drug Administration (FDA) approved finerenone (brand name Kerendia) to reduce urinary albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D). UACR is a measure of kidney damage, and reducing […]
Publication Alert: T1D Screening Consensus Guidance is Here
New Publication Alert! Breakthrough T1D spearheaded a paper titled “International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes” that was published in Diabetologia. This is an important step toward integrating general population screening for type 1 diabetes (T1D) into clinical practice globally. Read on to learn more about […]
Training the Next Generation: Meet our Research Interns
To accomplish our mission of a world without type 1 diabetes (T1D), one thing is clear: the more minds we have thinking about T1D, the better. That’s why Breakthrough T1D brings in interns each year, including in our Research department. Training the next generation isn’t just about career development—it’s about fresh eyes, new ideas, diverse […]
Abbott’s Dual Glucose-Ketone Sensing Technology Approved in the U.S.
What’s Happening? The U.S. Food and Drug Administration (FDA) approved Abbott’s Libre Duo 10 Day, the world’s first two-in-one sensor that monitors both glucose and ketones. People with diabetes ages two and up will soon be able to access this technology in the U.S. This follows from its recent approval in Europe earlier this year. […]
A New Tool to Accurately Diagnose Type 1 in Adults
Misdiagnosing adults with type 1 diabetes (T1D) is an all-too-common problem that can have tragic consequences. Breakthrough T1D and IQVIA partnered up to tackle it—and the results were just published.
An Interview with Breakthrough T1D-Funded Researchers
A cornerstone of Breakthrough T1D is awarding funding to scientists, researchers, and clinicians who are embarking on promising type 1 diabetes (T1D) research projects. The research we fund spans across the entire spectrum of T1D, including underlying biological and genetic causes, new approaches to cures, advanced technologies, clinical trials, and more. Here, we feature Remi […]
Tips for Smooth Insulin Injections
We’ve all had moments where insulin injections just don't go the way you want. Get tips for a smooth injection every time.
